B. Paul Morgan - Concepedia

Author

B. Paul Morgan

Also Known As

Accelerating Medicines Partnership (AMP) RA/SLE Network, B MORGAN, B Morgan, B P MORGAN, B P Morgan, B PAUL MORGAN, B Paul Morgan, B. Morgan, B. P. MORGAN, B. P. Morgan

990

Publications

39K

Citations

102

H-Index

369

Concepts

All Affiliations

Cardiff University University of Wales UK Dementia Research Institute University of Oxford Institute of Infection and Immunity

About

B. Paul Morgan is an author at Cardiff University specializing in medicine, immunology, and complement system.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	16	18	1.3K
2	Engineering	9	9	377
3	Business	3	3	68
4	Education	1	1	14
5	Management	1	1	14

B. Paul Morgan

444

Publications

31.5K

Citations

H-Index

Page 1

	Year	Citations
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference Timothy H.J. Goodship, H. Terence Cook, Fádi Fakhouri, Kidney International	2016	674
C3 glomerulopathy: consensus report Matthew C. Pickering, Vivette D. D’Agati, Carla Nester, Kidney International	2013	623
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure Fady I. Malik, James J. Hartman, Kathleen A. Elias, Science Cardiac MuscleHeart FailureCardiovascular PharmacologyCytoskeletonMechanotransduction	2011	590
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Seppo Meri, B. Paul Morgan, Alun Davies, PubMed ImmunologyImmunologic MechanismAntigen ProcessingImmune SystemMw Complement Lysis	1990	544
IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis† Maria Isabel Leite, Saiju Jacob, Stuart Viegas, Brain	2008	508
Immunopathology of secondary‐progressive multiple sclerosis John W. Prineas, Eunice E. Kwon, Eun‐Sook Cho, Annals of Neurology	2001	446
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome Elena Goicoechea de Jorge, Claire L. Harris, Jorge Esparza-Gordillo, Proceedings of the National Academy of Sciences ImmunohematologyGeneticsComplement Factor BImmunologyHemolytic Uremic Syndrome	2006	443
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Mark S. Cragg, Suzanne M. Morgan, H.T. Claude Chan, Blood	2003	380
The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation Kathy Triantafilou, Timothy R. Hughes, Martha Triantafilou, Journal of Cell Science ApoptosisImmunologyCell DeathSublytic Mac AttackCell Death Mechanisms	2013	346
Soluble Forms of Toll-Like Receptor (TLR)2 Capable of Modulating TLR2 Signaling Are Present in Human Plasma and Breast Milk Emmanuel LeBouder, Julia E. Rey-Nores, Neil K. Rushmere, The Journal of Immunology Innate Immune SystemImmunologyImmune RegulationToll-like ReceptorInnate Immunity	2003	336

Page 1